FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2139686528> ?p ?o ?g. }

• W2139686528 endingPage "101" @default.
• W2139686528 startingPage "101" @default.
• W2139686528 abstract "Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either. There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that ondansetron is effective as an adjunct drug in improving the symptoms of schizophrenia. This is a two center, six-month, double-blind placebo controlled, factorial design study of ondansetron and/or simvastatin added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. This will be a 2 × 2 design, with 54 patients in each cell, giving a total of 216 patients over three years. There will be a screening, a randomization and seven follow-up visits. Full clinical and neurocognitive assessments will be carried out at baseline (randomization), 14 weeks and at 26 weeks, while the positive and negative syndrome scale (PANSS), pill count and side effects checklist will be carried out at every visit. Simvastatin will be started at 20 mg once daily (OD), this will be increased to 40 mg after four weeks. Ondansetron will be administered in an 8 mg dose. Anti-inflammatory treatments have been shown to have some beneficial effects in schizophrenia. Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared to treatment as usual. The aim of this study is to establish the degree of improvement in negative symptoms with the addition of ondansetron and/or simvastatin to treatment as usual. ClinicalTrails.gov NCT01602029" @default.
• W2139686528 created "2016-06-24" @default.
• W2139686528 creator A5002936880 @default.
• W2139686528 creator A5008199395 @default.
• W2139686528 creator A5009512673 @default.
• W2139686528 creator A5019095577 @default.
• W2139686528 creator A5034270935 @default.
• W2139686528 creator A5039234509 @default.
• W2139686528 creator A5045365390 @default.
• W2139686528 creator A5047579218 @default.
• W2139686528 creator A5055285583 @default.
• W2139686528 creator A5077898087 @default.
• W2139686528 creator A5080581341 @default.
• W2139686528 creator A5087656004 @default.
• W2139686528 creator A5089682497 @default.
• W2139686528 date "2013-01-01" @default.
• W2139686528 modified "2023-10-16" @default.
• W2139686528 title "Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial" @default.
• W2139686528 cites W1595667478 @default.
• W2139686528 cites W1978508380 @default.
• W2139686528 cites W2010407531 @default.
• W2139686528 cites W2020773530 @default.
• W2139686528 cites W2024555504 @default.
• W2139686528 cites W2030396834 @default.
• W2139686528 cites W2039733943 @default.
• W2139686528 cites W2050038709 @default.
• W2139686528 cites W2059922970 @default.
• W2139686528 cites W2068011539 @default.
• W2139686528 cites W2068144727 @default.
• W2139686528 cites W2072102207 @default.
• W2139686528 cites W2130326256 @default.
• W2139686528 cites W2140606211 @default.
• W2139686528 cites W2149639459 @default.
• W2139686528 cites W2327612061 @default.
• W2139686528 cites W2500007653 @default.
• W2139686528 cites W2520316538 @default.
• W2139686528 cites W936667257 @default.
• W2139686528 doi "https://doi.org/10.1186/1745-6215-14-101" @default.
• W2139686528 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3680972" @default.
• W2139686528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23782463" @default.
• W2139686528 hasPublicationYear "2013" @default.
• W2139686528 type Work @default.
• W2139686528 sameAs 2139686528 @default.
• W2139686528 citedByCount "11" @default.
• W2139686528 countsByYear W21396865282014 @default.
• W2139686528 countsByYear W21396865282015 @default.
• W2139686528 countsByYear W21396865282017 @default.
• W2139686528 countsByYear W21396865282018 @default.
• W2139686528 countsByYear W21396865282019 @default.
• W2139686528 countsByYear W21396865282020 @default.
• W2139686528 countsByYear W21396865282021 @default.
• W2139686528 crossrefType "journal-article" @default.
• W2139686528 hasAuthorship W2139686528A5002936880 @default.
• W2139686528 hasAuthorship W2139686528A5008199395 @default.
• W2139686528 hasAuthorship W2139686528A5009512673 @default.
• W2139686528 hasAuthorship W2139686528A5019095577 @default.
• W2139686528 hasAuthorship W2139686528A5034270935 @default.
• W2139686528 hasAuthorship W2139686528A5039234509 @default.
• W2139686528 hasAuthorship W2139686528A5045365390 @default.
• W2139686528 hasAuthorship W2139686528A5047579218 @default.
• W2139686528 hasAuthorship W2139686528A5055285583 @default.
• W2139686528 hasAuthorship W2139686528A5077898087 @default.
• W2139686528 hasAuthorship W2139686528A5080581341 @default.
• W2139686528 hasAuthorship W2139686528A5087656004 @default.
• W2139686528 hasAuthorship W2139686528A5089682497 @default.
• W2139686528 hasBestOaLocation W21396865281 @default.
• W2139686528 hasConcept C118552586 @default.
• W2139686528 hasConcept C126322002 @default.
• W2139686528 hasConcept C142724271 @default.
• W2139686528 hasConcept C168563851 @default.
• W2139686528 hasConcept C170493617 @default.
• W2139686528 hasConcept C204787440 @default.
• W2139686528 hasConcept C27081682 @default.
• W2139686528 hasConcept C2775864247 @default.
• W2139686528 hasConcept C2776134451 @default.
• W2139686528 hasConcept C2776412080 @default.
• W2139686528 hasConcept C2777170512 @default.
• W2139686528 hasConcept C2779419675 @default.
• W2139686528 hasConcept C2779727114 @default.
• W2139686528 hasConcept C2780135775 @default.
• W2139686528 hasConcept C2780325297 @default.
• W2139686528 hasConcept C2780580376 @default.
• W2139686528 hasConcept C2780948584 @default.
• W2139686528 hasConcept C513476851 @default.
• W2139686528 hasConcept C71924100 @default.
• W2139686528 hasConceptScore W2139686528C118552586 @default.
• W2139686528 hasConceptScore W2139686528C126322002 @default.
• W2139686528 hasConceptScore W2139686528C142724271 @default.
• W2139686528 hasConceptScore W2139686528C168563851 @default.
• W2139686528 hasConceptScore W2139686528C170493617 @default.
• W2139686528 hasConceptScore W2139686528C204787440 @default.
• W2139686528 hasConceptScore W2139686528C27081682 @default.
• W2139686528 hasConceptScore W2139686528C2775864247 @default.
• W2139686528 hasConceptScore W2139686528C2776134451 @default.
• W2139686528 hasConceptScore W2139686528C2776412080 @default.
• W2139686528 hasConceptScore W2139686528C2777170512 @default.
• W2139686528 hasConceptScore W2139686528C2779419675 @default.
• W2139686528 hasConceptScore W2139686528C2779727114 @default.

• next